Gregorio Marañón Public Hospital successfully completes the world’s first clinical trial of thyTreg cells in pediatric heart transplantation, paving the way for a novel approach to preventing rejection.
Gregorio Marañón Hospital, a public healthcare institution in the Community of Madrid, has completed the world’s first clinical trial using thymus-derived regulatory T cells (thyTreg) in children undergoing heart transplantation. This innovative strategy could transform the management of immune rejection in pediatric transplant recipients. Preliminary results from the study show that a single administration of […]
Closer to a Heart Transplant That Lasts a Lifetime.
Researchers at Gregorio Marañón Hospital in Madrid have completed the world’s first clinical trial using thymus-derived regulatory T cells (thyTregs) in children who have undergone heart transplantation. The innovative therapy aims to help the immune system accept the transplanted organ and reduce the risk of rejection. Preliminary results are highly encouraging. Ten children under the […]
Global thyTreg Cell Trial Advances Rejection Prevention in Pediatric Heart Transplantation
Global thyTreg Trial Advances Rejection Prevention in Pediatric Heart Transplantation Gregorio Marañón Hospital has conducted the world’s first clinical trial using thymus-derived regulatory T cells (thyTreg) in children who have undergone heart transplantation. This innovative approach opens a new avenue for preventing immune rejection in pediatric transplant recipients. Initial results show that a single administration […]
A Landmark Global Trial Using thyTreg Cells Opens a New Path to Prevent Rejection in Pediatric Heart Transplantation
Gregorio Marañón Completes the World’s First Clinical Trial Using thyTreg Cells in Pediatric Heart Transplant Patients Gregorio Marañón Hospital has successfully completed the world’s first clinical trial using thymus-derived regulatory T cells (thyTreg) in children undergoing heart transplantation, introducing an innovative therapeutic approach that could open a new pathway for preventing immune rejection in pediatric […]
Gregorio Marañón Successfully Completes the World’s First Trial to Prevent Rejection in Pediatric Transplants
The Madrid-based hospital used thyTreg cells to enhance immune tolerance, paving the way for a reduction in the burden of immunosuppressive drugs in transplanted infants. None of the treated children showed signs of rejection or developed antibodies against the transplanted organ. Gregorio Marañón University General Hospital has announced the completion of the world’s first clinical […]
ThyTech in Actualidad Económica (El Mundo)
Actualidad Económica has published an in‑depth feature on ThyTech’s scientific and business model, highlighting our platform of cell therapies derived from discarded pediatric thymus tissue and its potential to transform the treatment of autoimmune and inflammatory diseases, as well as transplant rejection. The article underscores our commitment to translational science, public‑private collaboration, and an ethical […]
Gregorio Marañón Public Hospital successfully completes the world’s first clinical trial of thyTreg cells in pediatric heart transplantation, paving the way for a novel approach to preventing rejection.
Gregorio Marañón Hospital, a public healthcare institution in the Community of Madrid, has completed the world’s first clinical trial using thymus-derived regulatory T cells (thyTreg) in children undergoing heart transplantation. This innovative strategy could transform the management of immune rejection in pediatric transplant recipients. Preliminary results from the study show that a single administration of […]
Rafael Correa Rocha highlights advances in pediatric heart transplantation on RTVE 24h
In this interview for RTVE 24h, Rafael Correa Rocha, CSO and Board Member of Thytech, discusses the current landscape of pediatric heart transplantation and the advances helping to improve therapeutic options for young patients. During the conversation, he highlights the main challenges facing the field and the role of biomedical innovation in shaping the future […]
ThyTech presents its cell therapy at the 8th Treg-Directed Therapies Summit 2026 in Boston
Dr. Rafael Correa-Rocha, CSO of ThyTech, participated for the second consecutive year as an invited speaker at the 8th Treg-Directed Therapies Summit 2026 in Boston, where he presented clinical advances of the thyTregs™ cell therapy, featured as one of the event’s highlighted sessions. ThyTech showcased favorable results in pediatric heart transplant patients and progress in […]
The Spanish project ThyTech is presented at the 8th Treg-Directed Therapies Summit 2026 in Boston
Dr. Rafael Correa-Rocha, founder and Chief Scientific Officer (CSO) of ThyTech and researcher at the Gregorio Marañón Health Research Institute (Madrid, Spain), has participated for the second consecutive year as an invited speaker at the 8th Treg-Directed Therapies Summit 2026, which has just concluded in Boston. He delivered the presentation “Uncovering Clinical Advances with thyTregs™ […]
